# BlossomHill Therapeutics, Inc.

> BlossomHill Therapeutics is a San Diego clinical-stage biopharmaceutical company designing small-molecule precision medicines for cancer and autoimmune disease. Founded in 2020 by drug designer J. Jean Cui and biotech veteran Y. Peter Li - the team behind Turning Point Therapeutics (acquired by Bristol Myers Squibb in 2022) - the company is advancing a wholly-owned pipeline led by BH-30643, a first-in-class macrocyclic OMNI-EGFR inhibitor for EGFR-mutant non-small cell lung cancer, and BH-30236, a CLK inhibitor targeting aberrant RNA splicing in AML and high-risk MDS.

- **Founded:** 2020
- **Headquarters:** San Diego, California, United States
- **Founders:** J. Jean Cui (Co-Founder, President & CEO), Y. Peter Li (Co-Founder & Executive Chairman)
- **Team size:** ~61 employees
- **Products:** BH-30643 (OMNI-EGFR inhibitor), BH-30236 (CLK inhibitor), Discovery pipeline
- **Notable:** Founders previously built Turning Point Therapeutics, acquired by Bristol Myers Squibb in 2022 (~$4.1B)., Founder J. Jean Cui designed three FDA-approved drugs: crizotinib (XALKORI), lorlatinib (LORBRENA) and repotrectinib (AUGTYRO)., Raised approximately $257 million in total funding by December 2025.

## Products & services

- **BH-30643 (OMNI-EGFR inhibitor)** — A first-in-class, macrocyclic, CNS-active, mutant-selective EGFR inhibitor for EGFR- and HER2-mutant non-small cell lung cancer (NSCLC), in the Phase 1/2 SOLARA trial. Clinical data expected in 2026.
- **BH-30236 (CLK inhibitor)** — A novel macrocyclic CLK inhibitor targeting aberrant RNA splicing, in Phase 1/1b dose escalation (including a venetoclax combination) for relapsed/refractory acute myeloid leukemia (AML) and higher-risk myelodysplastic syndrome (HR-MDS).
- **Discovery pipeline** — Wholly-owned oncology and autoimmune discovery programs advancing toward IND-enabling studies, built on a design-first chemistry approach.

## Achievements

- Founders previously built Turning Point Therapeutics, acquired by Bristol Myers Squibb in 2022 (~$4.1B).
- Founder J. Jean Cui designed three FDA-approved drugs: crizotinib (XALKORI), lorlatinib (LORBRENA) and repotrectinib (AUGTYRO).
- Raised approximately $257 million in total funding by December 2025.
- Advanced two wholly-owned programs into Phase 1/2 clinical trials.
- Presented the design and discovery of OMNI-EGFR inhibitor BH-30643 at the 2025 AACR Annual Meeting.

## Latest updates

- **2025-12** — Raised $84 million Series B extension led by Janus Henderson, Brahma Capital and BioTrack Capital, bringing total capital to ~$257 million.
- **2025-04** — Presented design and discovery of OMNI-EGFR inhibitor BH-30643 at the 2025 AACR Annual Meeting.
- **2024-02** — Closed $100 million Series B financing led by Colt Ventures.
- **2026** — Clinical data from the Phase 1/2 SOLARA trial of BH-30643 and updates on BH-30236 expected.

## Links

- Website: https://bhtherapeutics.com
- LinkedIn: http://www.linkedin.com/company/blossomhill-therapeutics-inc
- Twitter/X: https://twitter.com/bhtherapeutics

---

Profile page: https://yespress.io/blossomhill-therapeutics-inc
Published by YesPress — https://yespress.io
Last updated: 2026-06-15